Mammoth Biosciences
Dinah Sah is an accomplished scientist with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Co-Executive Director at Caribbean Science Foundation since February 2012, Dinah also holds positions as Chief Scientific Officer and member of the Scientific Advisory Board at Voyager Therapeutics, Inc. since March 2014. Additional roles include President and Director at CADSTI-NEW ENGLAND INC. from April 2014 onward. Prior experience includes influential positions at Alnylam Pharmaceuticals, Biogen Idec, and Signal Pharmaceuticals, showcasing a robust background in research leadership, particularly in neuroscience and oncology. Dinah holds a B.S. in Biology from the Massachusetts Institute of Technology and a PhD in Neurobiology from Harvard University.
This person is not in the org chart
This person is not in any offices
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.